AAPL324.96-0.17 (-0.05%) ▼|ABBV261.72+1.73 (+0.67%) ▲|ABT110.47+1.54 (+1.41%) ▲|ACN187.68-0.41 (-0.22%) ▼|ADBE279.79-6.29 (-2.20%) ▼|AMAT438.46-3.39 (-0.77%) ▼|AMD457.06-2.55 (-0.55%) ▼|AMGN442.84+4.72 (+1.08%) ▲|AMT172.92-3.10 (-1.76%) ▼|AMZN254.98+0.06 (+0.02%) ▲|AVGO367.24-2.44 (-0.66%) ▼|AXP329.98+5.79 (+1.79%) ▲|BA208.87+3.21 (+1.56%) ▲|BAC62.60+0.61 (+0.98%) ▲|BKNG199.60+3.91 (+2.00%) ▲|BLK1,107.08-21.02 (-1.86%) ▼|BMY67.66+0.74 (+1.11%) ▲|BNY162.04+1.53 (+0.95%) ▲|BRK-B505.24+2.91 (+0.58%) ▲|C134.34+1.80 (+1.36%) ▲|CAT792.28+13.12 (+1.68%) ▲|CL90.10+0.47 (+0.52%) ▲|CMCSA26.81+0.51 (+1.94%) ▲|COF216.60+5.26 (+2.49%) ▲|COP137.20+1.01 (+0.74%) ▲|COST928.48-11.48 (-1.22%) ▼|CRM256.93-1.18 (-0.46%) ▼|CSCO109.46-0.29 (-0.26%) ▼|CVS97.23-0.37 (-0.38%) ▼|CVX211.78+0.73 (+0.35%) ▲|DE698.37+22.29 (+3.30%) ▲|DHR209.91+2.98 (+1.44%) ▲|DIS107.98+1.76 (+1.66%) ▲|DUK120.56+0.17 (+0.14%) ▲|EMR148.98+1.35 (+0.91%) ▲|FDX316.54-8.34 (-2.57%) ▼|GD364.07-5.34 (-1.45%) ▼|GE329.50-1.59 (-0.48%) ▼|GEV921.94+23.41 (+2.61%) ▲|GILD149.61-0.31 (-0.21%) ▼|GM84.87-0.76 (-0.89%) ▼|GOOG333.78+1.75 (+0.53%) ▲|GOOGL337.12+2.10 (+0.63%) ▲|GS1,004.42+1.86 (+0.19%) ▲|HD318.51-1.26 (-0.39%) ▼|HON206.07-3.91 (-1.86%) ▼|IBM231.70+0.30 (+0.13%) ▲|INTC90.05+1.08 (+1.21%) ▲|INTU342.94-1.99 (-0.58%) ▼|ISRG371.88+2.63 (+0.71%) ▲|JNJ275.21+4.02 (+1.48%) ▲|JPM356.22+1.27 (+0.36%) ▲|KO88.24+0.24 (+0.27%) ▲|LIN487.45+0.69 (+0.14%) ▲|LLY1,160.08+0.08 (+0.01%) ▲|LMT531.55-12.95 (-2.38%) ▼|LOW199.84-0.21 (-0.11%) ▼|LRCX288.32-1.88 (-0.65%) ▼|MA588.14+7.04 (+1.21%) ▲|MCD260.95-0.16 (-0.06%) ▼|MDLZ62.45+0.84 (+1.36%) ▲|MDT92.18+0.14 (+0.15%) ▲|META592.85+14.31 (+2.47%) ▲|MMM168.75-1.49 (-0.88%) ▼|MO69.56-0.01 (-0.01%) ▼|MRK151.64+1.78 (+1.19%) ▲|MS211.82+0.78 (+0.37%) ▲|MSFT496.82-4.20 (-0.84%) ▼|MU956.08+22.64 (+2.43%) ▲|NEE83.10+0.17 (+0.21%) ▲|NFLX82.73+1.92 (+2.38%) ▲|NKE38.24+0.12 (+0.31%) ▲|NOW136.72-6.18 (-4.32%) ▼|NVDA224.41+6.97 (+3.21%) ▲|ORCL145.75+4.43 (+3.13%) ▲|PEP140.52+0.73 (+0.52%) ▲|PFE29.02+0.47 (+1.65%) ▲|PG147.64+1.43 (+0.98%) ▲|PLTR169.46-10.46 (-5.81%) ▼|PM187.94+0.79 (+0.42%) ▲|QCOM169.96+3.35 (+2.01%) ▲|RTX200.78-4.38 (-2.13%) ▼|SBUX106.72+0.57 (+0.54%) ▲|SCHW108.24-0.04 (-0.04%) ▼|SO88.31+0.22 (+0.25%) ▲|SPG210.20-1.67 (-0.79%) ▼|T25.95-0.05 (-0.19%) ▼|TMO608.54+8.04 (+1.34%) ▲|TMUS187.30+5.14 (+2.82%) ▲|TSLA357.01+0.92 (+0.26%) ▲|TXN254.80+1.46 (+0.58%) ▲|UBER76.45+1.21 (+1.61%) ▲|UNH399.66+3.36 (+0.85%) ▲|UNP289.73-0.89 (-0.31%) ▼|UPS103.01+0.35 (+0.34%) ▲|USB62.77+1.56 (+2.55%) ▲|V378.40+5.73 (+1.54%) ▲|VZ50.22-0.08 (-0.16%) ▼|WFC89.27+2.23 (+2.56%) ▲|WMT106.09+0.17 (+0.16%) ▲|XOM164.15-0.40 (-0.24%) ▼|AAPL324.96-0.17 (-0.05%) ▼|ABBV261.72+1.73 (+0.67%) ▲|ABT110.47+1.54 (+1.41%) ▲|ACN187.68-0.41 (-0.22%) ▼|ADBE279.79-6.29 (-2.20%) ▼|AMAT438.46-3.39 (-0.77%) ▼|AMD457.06-2.55 (-0.55%) ▼|AMGN442.84+4.72 (+1.08%) ▲|AMT172.92-3.10 (-1.76%) ▼|AMZN254.98+0.06 (+0.02%) ▲|AVGO367.24-2.44 (-0.66%) ▼|AXP329.98+5.79 (+1.79%) ▲|BA208.87+3.21 (+1.56%) ▲|BAC62.60+0.61 (+0.98%) ▲|BKNG199.60+3.91 (+2.00%) ▲|BLK1,107.08-21.02 (-1.86%) ▼|BMY67.66+0.74 (+1.11%) ▲|BNY162.04+1.53 (+0.95%) ▲|BRK-B505.24+2.91 (+0.58%) ▲|C134.34+1.80 (+1.36%) ▲|CAT792.28+13.12 (+1.68%) ▲|CL90.10+0.47 (+0.52%) ▲|CMCSA26.81+0.51 (+1.94%) ▲|COF216.60+5.26 (+2.49%) ▲|COP137.20+1.01 (+0.74%) ▲|COST928.48-11.48 (-1.22%) ▼|CRM256.93-1.18 (-0.46%) ▼|CSCO109.46-0.29 (-0.26%) ▼|CVS97.23-0.37 (-0.38%) ▼|CVX211.78+0.73 (+0.35%) ▲|DE698.37+22.29 (+3.30%) ▲|DHR209.91+2.98 (+1.44%) ▲|DIS107.98+1.76 (+1.66%) ▲|DUK120.56+0.17 (+0.14%) ▲|EMR148.98+1.35 (+0.91%) ▲|FDX316.54-8.34 (-2.57%) ▼|GD364.07-5.34 (-1.45%) ▼|GE329.50-1.59 (-0.48%) ▼|GEV921.94+23.41 (+2.61%) ▲|GILD149.61-0.31 (-0.21%) ▼|GM84.87-0.76 (-0.89%) ▼|GOOG333.78+1.75 (+0.53%) ▲|GOOGL337.12+2.10 (+0.63%) ▲|GS1,004.42+1.86 (+0.19%) ▲|HD318.51-1.26 (-0.39%) ▼|HON206.07-3.91 (-1.86%) ▼|IBM231.70+0.30 (+0.13%) ▲|INTC90.05+1.08 (+1.21%) ▲|INTU342.94-1.99 (-0.58%) ▼|ISRG371.88+2.63 (+0.71%) ▲|JNJ275.21+4.02 (+1.48%) ▲|JPM356.22+1.27 (+0.36%) ▲|KO88.24+0.24 (+0.27%) ▲|LIN487.45+0.69 (+0.14%) ▲|LLY1,160.08+0.08 (+0.01%) ▲|LMT531.55-12.95 (-2.38%) ▼|LOW199.84-0.21 (-0.11%) ▼|LRCX288.32-1.88 (-0.65%) ▼|MA588.14+7.04 (+1.21%) ▲|MCD260.95-0.16 (-0.06%) ▼|MDLZ62.45+0.84 (+1.36%) ▲|MDT92.18+0.14 (+0.15%) ▲|META592.85+14.31 (+2.47%) ▲|MMM168.75-1.49 (-0.88%) ▼|MO69.56-0.01 (-0.01%) ▼|MRK151.64+1.78 (+1.19%) ▲|MS211.82+0.78 (+0.37%) ▲|MSFT496.82-4.20 (-0.84%) ▼|MU956.08+22.64 (+2.43%) ▲|NEE83.10+0.17 (+0.21%) ▲|NFLX82.73+1.92 (+2.38%) ▲|NKE38.24+0.12 (+0.31%) ▲|NOW136.72-6.18 (-4.32%) ▼|NVDA224.41+6.97 (+3.21%) ▲|ORCL145.75+4.43 (+3.13%) ▲|PEP140.52+0.73 (+0.52%) ▲|PFE29.02+0.47 (+1.65%) ▲|PG147.64+1.43 (+0.98%) ▲|PLTR169.46-10.46 (-5.81%) ▼|PM187.94+0.79 (+0.42%) ▲|QCOM169.96+3.35 (+2.01%) ▲|RTX200.78-4.38 (-2.13%) ▼|SBUX106.72+0.57 (+0.54%) ▲|SCHW108.24-0.04 (-0.04%) ▼|SO88.31+0.22 (+0.25%) ▲|SPG210.20-1.67 (-0.79%) ▼|T25.95-0.05 (-0.19%) ▼|TMO608.54+8.04 (+1.34%) ▲|TMUS187.30+5.14 (+2.82%) ▲|TSLA357.01+0.92 (+0.26%) ▲|TXN254.80+1.46 (+0.58%) ▲|UBER76.45+1.21 (+1.61%) ▲|UNH399.66+3.36 (+0.85%) ▲|UNP289.73-0.89 (-0.31%) ▼|UPS103.01+0.35 (+0.34%) ▲|USB62.77+1.56 (+2.55%) ▲|V378.40+5.73 (+1.54%) ▲|VZ50.22-0.08 (-0.16%) ▼|WFC89.27+2.23 (+2.56%) ▲|WMT106.09+0.17 (+0.16%) ▲|XOM164.15-0.40 (-0.24%) ▼|
20.8 C
New York
Thursday, September 3, 2026

Tag: incidence

newssourceFORcompanyinformationcontent1releasesmarket

Darolutamide receives EU approval in third indication for patients with advanced prostate cancer

ORION CORPORATION
PRESS RELEASE
21 JULY 2025 at 10:30 EEST          

Euroopan Unionilta hyväksyntä darolutamidin kolmannelle käyttöaiheelle edennyttä eturauhassyöpää sairastavien potilaiden hoidossa

ORION OYJ
LEHDISTÖTIEDOTE
21.7.2025 klo 10.30

European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms – 
– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –

European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms – 
– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –

Technetium-99m Market Size to Reach USD 6.29 Billion by 2031, Growing at a CAGR of 3.9% | Exclusive Report by The Insight Partners

NEW YORK, July 18, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the global technetium-99m market is witnessing substantial...

Technetium-99m Market Size to Reach USD 6.29 Billion by 2031, Growing at a CAGR of 3.9% | Exclusive Report by The Insight Partners

NEW YORK, July 18, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the global technetium-99m market is witnessing substantial...

Nature Medicine Published Phase 1 Results of Innovent Biologics’ Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

SAN FRANCISCO and SUZHOU, China, July 16, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality...

Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities

Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER. BC, July 16, 2025 /PRNewswire/ -- As lawmakers weigh potential cuts to scientific research...

Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities

Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER. BC, July 16, 2025 /PRNewswire/ -- As lawmakers weigh potential cuts to scientific research...

Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities

Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER. BC, July 16, 2025 /CNW/ -- As lawmakers weigh potential cuts to scientific research...

Peanut Allergy Market Set to Grow at a 16% CAGR During the Study Period (2020-2034) Owing to Current Usage of Epinephrine, Anticipated Usage of...

The evolving peanut allergy treatment market landscape features clinical trials led by DBV Technologies (Viaskin Peanut Patch), Novartis (Remibrutinib), Aravax (PVX108), ALK-Abello (Sublingual...

G-Protein Coupled Receptor (GPCR) Targeting Technologies Market on the Rise

"Highlighting Strategic Alliances and Innovation, the Global GPCR Targeting Market Report Explores the Role of GPCRs in Drug Discovery and Therapeutics, Featuring Key Players...

A Statement from the Global Virus Network (GVN) on the Rapidly Escalating Measles Crisis in the U.S. and Worldwide

GVN is sounding the alarm over a sharp resurgence of measles cases in the United States and globally.

Senhwa Biosciences announces first patient dosed in NCI-sponsored pilot study of Pidnarulex (CX-5461) pharmacodynamics in patients with advanced solid tumors

TAIPEI and SAN DIEGO, July 15, 2025 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focusing on first-in-class therapeutics for...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsIncidence

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers